Plasma pTau217 Cutoffs for Clinical Use

• by Kathryn Wighton

• February 4, 2026

Neurogenic progression may falter in MDD

Postmortem multiomic analyses showed more quiescent neural stem cells and fewer neuroblasts, alongside broader hippocampal molecular changes.

• by Andrea Surnit

• August 26, 2026

• 4 min

FDA authorizes continuous ketone monitor

Patients aged 2 years and older with diabetes are eligible to use the wearable.

• by Kathryn Wighton

• August 26, 2026

• 2 min

FDA approves tau PET imaging agent

The F18-labeled agent is indicated for brain PET imaging to identify tau neurofibrillary tangle pathology.

• by Kathryn Wighton

• August 14, 2026

• 2 min